Stop Smoking! Quitting at Any Age Reduces the Risk of Death After 70

Lifetime smoking history is a key determinant of mortality for people 70 and over and that quitting, even after 60, benefits individuals into their 70s, reports the American Journal of Preventive Medicine

Ann Arbor, MI, November 30, 2016 – Tobacco use continues to be a major cause of cancer and premature death. Most studies of cigarette smoking and mortality have focused on middle-aged populations, with fewer studies examining the impact of tobacco cessation on disease and mortality risk among the elderly. A new study published in the American Journal of Preventive Medicine, found that people aged 70 or older currently smoking were more than three times more likely to die than never-smokers, while former smokers were less likely to die the sooner they quit.

In the U.S., the number of individuals aged 70 years and older is expected to increase from 29.2 million (9.3% of the population) in 2012, to 63.6 million individuals (15.9%) in 2050. “U.S. adults aged 70 and older have a very high lifetime prevalence of cigarette smoking, so it’s important to examine the risks associated with smoking and the benefits of quitting at older ages among these individuals,” explained lead investigator Sarah H. Nash, PhD, who conducted the research as part of her postdoctoral training at the National Cancer Institute, NIH, Bethesda, MD.

Investigators reviewed data for more than 160,000 individuals aged 70 and over who participated in the NIH-AARP Diet and Health Study. They completed a questionnaire in 2004–2005 detailing their smoking use, and reported deaths were tracked until the end of 2011. Analyses conducted between 2014 and 2016 correlated age at death with self-reported age at smoking initiation and cessation and amount smoked after 70 years of age.

The 2004-2005 questionnaire assessed smoking intensity in cigarettes per day and smoking history through nine age periods. For this study, participants still smoking in their 70s were identified as current smokers, and former smokers were classified by the decade of life when quitting. For the follow-up, the National Death Index Plus was used to determine deaths, while ICD-9 and ICD-10 codes for smoking-related mortality were used to further identify outcomes. These included lung cancer; other smoking-related cancers, including bladder, colorectal, esophageal, head and neck, kidney and renal pelvis, liver, pancreatic and stomach cancers, and acute myeloid leukemia; heart disease; stroke; diabetes; and respiratory disease (e.g., pneumonia, influenza, chronic obstructive pulmonary disease, and allied conditions).

Data were adjusted for age, sex, level of education, and alcohol use. Since NIH-AARP participants are predominantly white, adjusting for race did not affect the results and was not included in the final models.
At the beginning of the study (2004-2005), the median age of participants was 75 years. Almost 56% were former smokers and 6% were current smokers. Males were less likely (31% vs 48% of females) to be never-smokers. Males smoked more than females (18.2 pack years vs 11.6 pack years), and males were more likely to have started smoking before 15 years (19% vs 9.5% of female smokers).

During an average follow-up of 6.4 years, almost 16% of the participants died. While 12.1% of the never smokers died, 16.2%, 19.7%, 23.9%, and 27.9% of former smokers who quit between ages 30–39, 40–49, 50–59, and 60–69 years died, respectively. Current smokers fared the worst, with 33.1% dying. Mortality rates for women were lower than men at each level of smoking use.

“These data show that age at smoking initiation and cessation, both key components of smoking duration, are important predictors of mortality in U.S. adults aged 70 years and older,” commented Dr. Nash. “In the NIH-AARP study population, younger age at initiation was associated with increased risk of mortality, highlighting the importance of youth and early-adult smoking on lifetime mortality risk, even among people who live to age 70 years. In addition, former smokers were at substantially reduced risk of mortality after age 70 years relative to current smokers, even those who quit in their 60s. These finding show that smoking cessation should be emphasized to all smokers, regardless of age.”

###

NOTES FOR EDITORS

“Cigarette Smoking and Mortality in Adults Aged 70 Years and Older: Results From the NIH-AARP Cohort,” by Sarah H. Nash, PhD, Linda M. Liao, PhD, Tamara B. Harris, MD, and Neal D. Freedman, PhD, DOI: http://dx.doi.org/10.1016/j.amepre.2016.09.036, published online in the American Journal of Preventive Medicine, in advance of Volume 52, Issue 3 (March 2017), by Elsevier.

Full text of this article is available to credentialed journalists upon request; contact Jillian B. Morgan at +1 734-936-1590 or ajpmmedia@elsevier.com. Journalists wishing to interview the authors should contact the NCI Press Office at +1 301-496-6641 or ncipressofficers@mail.nih.gov.

ABOUT THE AMERICAN JOURNAL OF PREVENTIVE MEDICINE

The American Journal of Preventive Medicine (www.ajpmonline.org) is the official journal of The American College of Preventive Medicine (www.acpm.org) and the Association for Prevention Teaching and Research (http://www.aotrweb.org/). It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.

The American Journal of Preventive Medicine, with an Impact Factor of 4.465, is ranked 14th in Public, Environmental, and Occupational Health titles and 16th in General & Internal Medicine titles for total number of citations according to the 2015 Journal Citation Reports® published by Thomson Reuters, 2016.

ABOUT ELSEVIER

Elsevier (www.elsevier.com) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the
boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions – among them ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Elsevier Research Intelligence (www.elsevier.com/research-intelligence), and ClinicalKey (www.clinicalkey.com) – and publishes over 2,500 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group (www.relx.com), a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com